Glucagon-Like Peptide 1, Neuroprotection and Neurodegenerative Disorders
Received Date: Jul 19, 2016 / Accepted Date: Jul 20, 2016 / Published Date: Jul 26, 2016
Glucagon-Like Peptide 1 (GLP-1) is a hormone belonging to the family of incretins whose peripheral insulinotropic effects in maintaining glucose homeostasis in response to food ingestion have long been known . GLP-1 (7-36), the most common and biologically active form, is a 30 amino acid peptide formed by post-translational cleavage of the pro-glucagon gene, it shows 50% homology to glucagon and it is mainly produced by enteroendocrine L-cells, which secrete it into the bloodstream. Although GLP-1 is blood brain barrier permeable, it is also synthesized in the brain and, in particular, in neurons of the nucleus tractus solitarius and of the intermediate reticular nucleus, which innervate the cerebral cortex, the hypothalamus, the amygdala, the hippocampal region and the paraventricular nucleus of the thalamus [2-5].
In the periphery, GLP-1 has a rather short half-life, being rapidly inactivated to GLP-1(9-36) amide by dipetidyl peptidase IV (DPP-IV) [6,7] an enzyme which is present in peripheral tissues, in body fluids (i.e., blood plasma and cerebrospinal fluid) and seems to localize also in the brain [8-10].
GLP-1 acts by activating a classic 7TM-G-protein coupled receptor named GLP-1R that, in the functional studies carried out so far, has been shown to stimulate adenylyl cyclase via the α subunit of the Gs protein, thus increasing intracellular cAMP levels and triggering a cascade of downstream events, such as activation of PKA, Epac2, PKC, MAPK and PI-3K pathways. However, it has been reported that GLP-1R can also couple to other G-protein α-subunits (i.e., Gq, o, i), although the functional meaning of this molecular promiscuity is not fully understood .
A milestone in the understanding of the physiological roles of the GLP-1/GLP-1R system was the isolation and characterization of the DPP-IV resistant, BBB permeable GLP-1R selective agonist exendin-4 and the selective antagonist exendin-(9-39) that permitted, in addition to in vitro experiments, to initiate various in vivo studies [12,13]. After exendin-4, liraglutide and lixisenatide have been produced as other GLP-1R agonists, whereas sitagliptin, saxagliptin and vidagliptin have been developed as selective DPP-IV inhibitors able to increase endogenous GLP-1 levels.
Although the interest for the GLP-1/GLP-1R system began in the field of diabetes treatment, it was soon clear that this hormone could also have important functions in the central nervous system.
The first evidence for a central physiological role of GLP-1, dates back to 1996 when it was shown that its intracerebroventricular (icv) administration, potently inhibited feeding in rats . However, it was only six years later that the neuroprotective role GLP-1 and exendin-4 was demonstrated for the first time . In that study, activation of GLP-1Rs was able to completely protect cultured rat hippocampal neurons from apoptotic death caused by glutamate excitotoxicity and to greatly reduce the in vivo ibotenic acid-induced depletion of choline acetyltransferase in the basal forebrain, leading the authors to hypothesise that “….such peptides may have potential for halting or reversing neurodegenerative processes in CNS disorders, such as Alzheimer’s disease…”
Since then, a large body of evidence has accumulated indicating that the activation of GLP-1Rs could represent a novel and effective disease modifying therapeutic strategy for treating neurodegenerative disorders.
Indeed, both in vitro and in vivo studies using validated animal models of Alzheimer’s (AD) and Parkinson’s (PD) diseases, Huntington’s chorea, amyotrophic lateral sclerosis and stroke have undoubtedly demonstrated the protective properties of GLP-1R agonists using both anatomo-pathological and behavioural analysis [16-18].
Significant neuroprotection has been reported also for the DPP-4 inhibitors sitagliptin and saxagliptin in PD and AD animal models, as well as in models of cerebral ischemia [19-21]. However, administration of sitagliptin to type 2 diabetic rats has been found to aggravate γ-tau phosphorylation in the hippocampus, thus highlighting the need of further studies before considering its use in AD .
As for the possible mechanisms through which GLP-1Rs trigger neuroprotection, several studies have revealed that these receptors are capable of stimulating neurite outgrowth, promoting adult neurogenesis with cell proliferation and survival, interrupting proapoptotic processes, and reducing neuroinflammation. In addition, they have beneficial effects for mitochondrial functions by means of different molecular mechanisms, including the stabilisation of the outer membrane through activation of the PI3K/AKT pathway, thus preventing the initiation of the apoptotic intrinsic pathway [17,18]. Indeed, mitochondria dysfunctions represent a common feature of different neurodegenerative disorders.
It is also worth noting that GLP-1 and GLP-1R have important effects also on learning and memory formation both under physiological and pathological conditions. In fact, in rodents, icv administration of GLP-1 or GLP-1R overexpression resulted in the enhancement of learning and memory, whereas GLP-1R knock-out caused significant deficits in cognitive processes [23,24]. The pro-amnesic effects of GLP-1R agonists are associated with the facilitation of hippocampal long term potentiation (LTP), the electrophysiological substrate of memory, as measured both in vitro and in vivo [25,26]. Accordingly, this synaptic plasticity phenomenon is impaired in GLP-1R knockout mice . Moreover, administration of GLP-1, GLP-1 agonists or DPP-IV inhibitors rescues LTP and the memory impairment caused by exogenous or endogenous β-amyloid, the self-aggregating peptide that accumulates AD brains [21,25-30].
Such overwhelming evidence has led to clinical trials in which GLP-1 mimetic have been tested for their efficacy in neurodegenerative disorders such as PD and AD.
In the first case, a single-blind proof of concept evaluated the progression of motor and nonmotor symptoms in a small group of PD patients treated with exenatide (exendin-4) administered subcutaneously for 12 months and found clinically relevant ameliorations both in motor and cognitive performances, evaluated by MDS-UPDRS (Movement Disorder Society Unified Parkinson’s Disease Rating Scale) and Mattis DRS-2 (Dementia Rating Scale 2) at the end of the therapy and after two months of washout . Most interestingly, the improvement persisted 12 months after the trial, with exanetide-treated patients showing a 5.6 and 5.3 point advantage on the MDS-UPDRS part 3 and on the Mattis DRS-2, respectively . These encouraging results have fuelled a larger, randomized, doubleblind, placebo-controlled phase II trial that is investigating the efficacy of a once weekly treatment with exenatide for 48 weeks in patients with moderate PD (NCT01971242).
As for AD, the efficacy of a six-month treatment with liraglutide has been evaluated in a small, randomized, double-blind, placebocontrolled trial on a total of 38 patients (18 liraglutide treated vs 20 placebo) . The primary outcome was the change of brain β-amyloid deposit assessed by PIB (Pittsburgh compound B) PET scan, whereas secondary outcomes were changes in CMRglc (Cerebral Metabolic Rate of glucose consumption) measured by FDG (Fluoro Deoxy Glucose) PET scan and changes in cognition assessed by the WMS-IV (Wechsler Memory Scale IV). The results show that CMRglc significantly declined in placebo controls but not in liraglutide-treated patients. Actually, the values were increased in this group, although insignificantly. However, β-amyloid load and cognitive scores were not different between the two groups. At the moment, there are two ongoing randomized, double blind, phase II trials: a pilot study that will evaluate safety, tolerability and efficacy of exenatide on MCI (Mild Cognitive Impairment) and early AD (NCT01255163) with an estimated enrolment of 100 patients, and a safety/efficacy study of liraglutide on mild AD with an estimated enrolment of 206 patie nts (NCT01843075).
In conclusion, pre-clinical and clinical studies point to stimulation of GLP-1 receptors as a novel and promising neuroprotective pharmacological intervention to treat different neurodegenerative disorders with the hope of slowing their progression. Will these promises become reality?
- Schmidt WE, Siegel EG, Creutzfeldt W (1985) Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 28: 704-707.
- Vrang N, Larsen PJ (2010) Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides. Prog Neurobiol 92: 442-462.
- Gu G, Roland B, Tomaselli K, Dolman CS, Lowe C, et al. (2013) Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication. J Comp Neurol 521:2235-2261.
- Trapp S, Richards JE (2013) The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant? Curr Opin Pharmacol 13: 964-969.
- Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, et al. (2015) Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab 4: 718-731.
- Deacon CF, Johnsen AH, Holst JJ (1995a)Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957.
- Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, et al. (1995 b) Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126-1131.
- Green BD, Flatt PR, Bailey CJ (2006) Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 3:159-165.
- Gault VA, Lennox R, Flatt PR (2015) Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes Obes Metab 17:403-413.
- Nassar NN, Al-Shorbagy MY, Arab HH, Abdallah DM (2015) Saxagliptin: a novel antiparkinsonian approach. Neuropharmacology 89: 308-317.
- Kim W, Egan JM (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60: 470-512.
- Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, et al. (1993) Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268: 19650-19655.
- Thorens B, Porret A, Bühler L, Deng SP, Morel P, et al. (1993) Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 1678-1682.
- Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72.
- Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH (2002) Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302: 881-888.
- Harkavyi A, Whitton PS (2010) Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 159: 495-501.
- Hölscher C (2014) Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol 221: T31-T41.
- Athauda D, Foltynie T (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov Today 21: 802-818.
- D’Amico M, Di Filippo C, Marfella R, Abbatecola AM, Ferraraccio F, et al. (2010) Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp Gerontol 45: 202-207.
- El-Sahar AE, Safar MM, Zaki HF, Attia AS, Ain-Shoka AA (2015) Sitagliptin attenuates transient cerebral ischemia/reperfusion injury in diabetic rats: implication of the oxidative-inflammatory-apoptotic pathway. Life Sci 126: 81-86.
- Kosaraju J, Gali CC, Khatwal RB, Dubala A, Chinni S, et al. (2013) Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. Neuropharmacology 72: 291-300.
- Kim DH, Huh JW, Jang M, Suh JH, Kim TW, et al. (2012) Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures. Neurobiol Dis 46:52-58.
- During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, et al. (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nature 9: 1173-79.
- Abbas T, Faivre E, Hölscher C (2009) Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav Brian Res 205: 265-271.
- Gault VA, Hölscher C (2008) GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 587: 112-117.
- McLean PL, Hölscher C (2014) Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 76: 57-67.
- Gengler S, McClean PL, McCurtin R, Gault VA, Hölscher C (2012) Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 33: 265-276.
- Han WN, Hölscher C, Yuan L, Yang W, Wang XH, et al. (2013) Liraglutide protects against amyloid-ß protein-induced impairment of spatial learning and memory in rats. Neurobiol Aging 34: 576-588.
- Cai HY, Hölscher C, Yue XH, Zhang SX, Wang XH, et al. (2014) Lixisenatide rescues spatial memory and synaptic plasticity from amyloid ß protein-induced impairments in rats. Neuroscience 277: 6-13.
- Jia XT, Ye-Tian, Yuan-Li, Zhang GJ, Liu ZQ, et al. (2016) Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-ß peptide-induced impairment of spatial learning and memory in rats. Physiol Behav 159: 72-79.
- Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, et al. (2013) Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest 123: 2730-2736.
- Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, et al. (2014) Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J Parkinsons Dis 4: 337-344.
- Gejl M, Gjedde A, Egefjord L, Møller A, Hansen SB, et al. (2016) In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Front Aging Neurosci 8: 108.
Citation: Fedele E, Ricciarelli R, Rebosio C (2016) Glucagon-Like Peptide 1, Neuroprotection and Neurodegenerative Disorders. J Biomol Res Ther 5:e151. Doi: 10.4172/2167-7956.1000e151
Copyright: © 2016 Fedele E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
- Total views: 8634
- [From(publication date): 9-2016 - Feb 20, 2019]
- Breakdown by view type
- HTML page views: 8535
- PDF downloads: 99